Seagen has been granted a patent for Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds. These compounds target MDR+ cells, including cancer cells, while also affecting nearby cells with lower expression of the targeted moiety. Claim 1 outlines the specific compound structure. GlobalData’s report on Seagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Seagen, Nanoparticle drug conjugates was a key innovation area identified from patents. Seagen's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer drug conjugates targeting mdr+ cells with bystander activity
A recently granted patent (Publication Number: US11857565B2) discloses a Ligand Drug Conjugate compound represented by a specific formula, along with its various structural components and configurations. The compound includes a Ligand Unit and drug-linker moieties, with the integer subscript p' ranging from 1 to 24. The drug linker moieties have defined structures, including specific amino acid sequences and subunits, as outlined in the claims of the patent.
Furthermore, the patent details the composition of the Ligand Drug Conjugate compound, specifying the structures of the drug linker moieties and their variations. The compound is designed to include an antibody Ligand Unit capable of selectively binding to a cancer cell antigen, emphasizing its potential application in targeted cancer therapy. The patent also provides ranges for the subscript p' integer, offering flexibility in the design and optimization of the compound for therapeutic purposes. Overall, the patent highlights a novel Ligand Drug Conjugate compound with specific structural features and targeting capabilities, paving the way for advancements in precision medicine and cancer treatment.
To know more about GlobalData’s detailed insights on Seagen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
